High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
MWN-AI** Summary
Mesoblast Limited recently presented compelling data on Ryoncil® (remestemcel-L-rknd) at the February 2026 Tandem Meetings of ASTCT and CIBMTR, highlighting its high survival rates in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The study revealed that both children and adults experienced similar survival outcomes, regardless of whether they were treated as second or third-line therapy, or were naïve to or resistant against ruxolitinib.
Ryoncil® holds the unique distinction of being the first FDA-approved mesenchymal stromal cell (MSC) therapy for SR-aGvHD, especially significant for pediatric patients under 12. The Emergency Investigational New Drug (EIND) program indicated that among 53 patients receiving Ryoncil® as third-line treatment, 15% passed away before completing their full treatment course compared to just 2% in the Phase 3 trial for second-line therapy. This stark contrast emphasizes the critical necessity of early intervention post-steroid failure to maximize treatment effectiveness and overall survival.
Intriguingly, adult patients in the EIND program evidenced at least equivalent day 100 survival rates as their pediatric counterparts, providing a robust rationale for forthcoming pivotal trials. These trials aim to investigate the early administration of Ryoncil® as part of a second-line treatment strategy for adults suffering from severe SR-aGvHD, a demographic far larger than the pediatric population.
Dr. Silviu Itescu, Chief Executive of Mesoblast, reinforced this urgency, stating that prompt treatment initiation with Ryoncil® is essential to enhance survival probabilities. If successful, the upcoming trial could lead to expanded usage of Ryoncil®, potentially transforming treatment paradigms for adults with severe SR-aGvHD, thereby impacting a broader patient population.
MWN-AI** Analysis
Mesoblast Limited's recent data presentation regarding Ryoncil® (remestemcel-L-rknd) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) highlights significant opportunities for investors and stakeholders in the biopharmaceutical market. With favorable survival rates observed in both children and adults, particularly when Ryoncil® is administered earlier in the treatment regimen, the company stands poised for enhanced growth potential.
The striking difference in survival rates between patients receiving Ryoncil® as a third-line treatment versus those receiving it as secondary treatment underscores a crucial insight: timing is pivotal in maximizing therapeutic outcomes. In the Emergency Investigational New Drug (EIND) program, only 2% of patients treated with Ryoncil® in the Phase 3 trial died before completing their treatment, compared to a concerning 15% in the EIND program—indicative of the urgency in initiating therapy against SR-aGvHD. This data strengthens the case for early implementation of Ryoncil® in clinical practices, which may be further validated by the imminent pivotal trial for adult patients.
From a market perspective, this evidence creates a robust rationale for an impending expansion of Ryoncil®'s label to adult populations—a demographic that is three times larger than its pediatric counterpart. Such an extension could significantly increase market penetration and revenue streams for Mesoblast. Furthermore, the strategic emphasis on the early use of this transformative therapy may lead to upcoming partnerships and collaborations that expand its distribution capabilities globally.
Investors should keep an eye on the outcome of the planned pivotal trial, as successful execution could not only validate the efficacy of Ryoncil® in wider demographics but also position Mesoblast favorably amidst increasing competition in the MSC therapy arena. Thus, maintaining a long position in Mesoblast shares appears prudent as the company capitalizes on this promising breakthrough in SR-aGvHD treatment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah.
The study results showed that Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease (SR-aGvHD) irrespective whether used in children or adults, as second or third line, and in ruxolitinib naive or resistant patients.1 Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication, and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).2
Importantly, of the 53 patients with SR-aGvHD who received Ryoncil® as ? third line treatment under the Emergency Investigational New Drug (EIND) program (89% grade III/IV disease), 15% died before being able to complete a full treatment course of Ryoncil® compared with only 2% of patients who received Ryoncil® as second-line in the Phase 3 trial MSB-GVHD001. These results emphasize the importance of using Ryoncil® as early as possible after steroid resistance in acute GVHD in order to complete a full treatment course and maximize survival.
Additionally, adult patients in the EIND program of Ryoncil® had at least as favorable day 100 survival as children in the EIND program, providing strong support and rationale for the planned pivotal trial of early use of Ryoncil® as part of the second-line treatment regimen in adults with severe SR-aGvHD. The trial is expected to commence enrollment this quarter after protocol approval by the trial's central Institutional Review Board (IRB). If successful, the trial will support label extension of Ryoncil® for use in adults - a population approximately three times the size of the pediatric SR-aGvHD population.
“Treatment initiation as early as possible is essential in order to give Ryoncil® the best chance to save as many precious lives as possible,” said Mesoblast Chief Executive Dr. Silviu Itescu. "The Phase 3 trial in adults with SR-aGvHD will position Ryoncil® as the earliest treatment regimen for severe disease after steroid resistance."
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
References / Footnotes
- Kurtzberg J, et al. Remestemcel-L-rknd (Ryoncil) Improves Survival After Failure of Second-Line Treatment for SR-aGVHD [Poster presentation]. 2026 Transplantation & Cellular Therapy Tandem Meetings
- Please see the full Prescribing Information at www.ryoncil.com
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | Media – Australia |
| Allison Worldwide | BlueDot Media |
| Emma Neal | Steve Dabkowski |
| T: +1 603 545 4843 | T: +61 419 880 486 |
| E: emma.neal@allisonworldwide.com | E: steve@bluedot.net.au |
FAQ**
How does the recent data on Ryoncil® impact the valuation of Mesoblast Ltd Ord MEOBF in the context of its competitive landscape in cellular therapies for inflammatory diseases?
What are the implications of the Phase 3 trial for adults with SR-aGvHD on the future market demand for Mesoblast Ltd Ord MEOBF's products, particularly in the context of survival outcomes?
Given the strong intellectual property portfolio of Mesoblast Ltd Ord MEOBF, how might potential patent expirations impact its market positioning and revenue streams in the next few years?
With the planned pivotal trial for Ryoncil® expected to commence enrollment soon, what are the potential risks and rewards associated with investing in Mesoblast Ltd Ord MEOBF at this stage?
**MWN-AI FAQ is based on asking OpenAI questions about Mesoblast Limited (NASDAQ: MESO).
NASDAQ: MESO
MESO Trading
-3.57% G/L:
$15.13 Last:
97,266 Volume:
$15.19 Open:
